The hypervalent orphan drug, ‘Soliris’, has been a target for a clinical trial to improve indication in Korea
A clinical trial will be conducted to improve indication for the paroxysmal nocturnal hemoglobinuria (PHN) treatment ‘Soliris (generic name: eculizumab)’ reaching KRW 400 million administration expenses every year.
The Ministry of Food and Drug Safety has approved the Phase 3 clinical trial of S...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
